collect
analyz
data
laboratori
examin
includ
peripher
lymphocyt
subset
analyz
compar
sever
nonsever
patient
patient
recruit
diagnos
sever
infect
median
age
year
male
common
symptom
fever
short
breath
expector
fatigu
dri
cough
myalgia
sever
case
tend
lower
lymphocyt
count
higher
leukocyt
count
neutrophillymphocyteratio
nlr
well
lower
percentag
monocyt
eosinophil
basophil
sever
case
demonstr
elev
level
infectionrel
biomark
inflammatori
cytokin
number
cell
significantli
decreas
hamper
sever
case
lower
level
helper
cell
sever
group
percentag
helper
cell
increas
memori
helper
cell
decreas
sever
case
patient
also
lower
level
regulatori
cell
obvious
damag
sever
case
novel
coronaviru
might
mainli
act
lymphocyt
especi
lymphocyt
surveil
nlr
lymphocyt
subset
help
earli
screen
critic
ill
diagnosi
treatment
outbreak
sever
acut
respiratori
syndrom
coronaviru
first
emerg
wuhan
decemb
rapidli
spread
throughout
china
past
two
month
consid
ongo
outbreak
china
fast
worldwid
spread
coronaviru
diseas
infect
led
declar
public
health
emerg
intern
concern
world
health
organ
januari
feb
total
laboratoryconfirm
case
identifi
china
primarili
wuhan
fatal
case
accord
data
chines
govern
offici
report
report
like
occur
older
men
comorbid
weaker
immun
function
new
type
highli
contagi
diseas
human
pathophysiolog
unusu
high
pathogen
complet
understood
yet
sever
studi
shown
increas
amount
proinflammatori
cytokin
serum
associ
pulmonari
inflamm
extens
lung
damag
sar
merscov
infect
recent
howev
littl
known
lymphocyt
subset
immun
respons
patient
retrospect
singlecent
studi
aim
analyz
express
infect
relat
biomark
inflammatori
cytokin
lymphocyt
subset
flow
cytometri
laboratoryconfirm
case
compar
differ
sever
case
nonsever
one
retrospect
recruit
total
patient
januari
februari
tongji
hospit
largest
comprehens
medic
treatment
center
central
china
specif
hospit
treatment
sever
patient
covid
wuhan
design
govern
studi
perform
accord
tongji
hospit
ethic
committe
irb
id
written
inform
consent
waiv
ethic
commiss
design
hospit
emerg
infecti
diseas
sever
judg
accord
fifth
revis
trial
version
novel
coronaviru
pneumonia
diagnosi
treatment
guidanc
met
criterion
follow
defin
severetyp
respiratori
distress
respiratori
rate
per
minut
oxygen
satur
rest
state
arteri
blood
oxygen
partial
pressur
oxygen
concentr
data
includ
demograph
data
medic
histori
symptom
sign
laboratori
find
collect
patient
medic
record
laboratori
result
includ
blood
routin
lymphocyt
subset
infectionrel
biomark
inflammatori
cytokin
immunoglobulin
complement
protein
total
number
lymphocyt
peripher
blood
count
hemocytomet
lymphocyt
subset
percentag
analyz
facscanto
flow
cytomet
patient
admiss
absolut
number
differ
lymphocyt
subset
calcul
multipli
percentag
total
lymphocyt
count
pmaionomycinstimul
lymphocyt
function
assay
perform
describ
previous
percentag
posit
cell
differ
cell
subset
defin
function
data
review
train
team
physician
tongji
hospit
confirm
case
defin
posit
realtim
reversetranscriptas
polymerasechain
reaction
rtpcr
assay
nasal
pharyng
swab
specimen
accord
guidanc
receipt
sampl
viral
rna
extract
perform
use
magnet
viral
rnadna
extract
kit
autom
nucleic
acid
extract
system
tianlong
xian
china
accord
manufactur
instruct
follow
polymerasechainreact
pcr
screen
presenc
specif
commerci
kit
tianlong
xian
china
volum
pcr
mixtur
contain
reaction
solut
probe
taq
nucleic
acid
condit
amplif
includ
revers
transcript
min
predenatur
min
follow
cycl
cycl
fluoresc
detect
cycl
threshold
valu
ctvalu
defin
posit
test
base
recommend
nation
institut
viral
diseas
control
prevent
china
describ
categor
variabl
frequenc
rate
percentag
continu
variabl
mean
standard
deviat
sd
median
interquartil
rang
iqr
valu
independ
group
test
use
comparison
mean
continu
variabl
normal
distribut
convers
mannwhitney
u
test
use
continu
variabl
normal
distribut
proport
categor
variabl
compar
use
test
statist
analys
perform
use
spss
statist
packag
social
scienc
version
softwar
spss
inc
twosid
pvalu
less
consid
statist
signific
moreov
sever
patient
significantli
like
short
breath
fatigu
vs
p
vs
p
respect
nonsever
patient
tabl
present
laboratori
find
patient
among
patient
underw
laboratori
examin
admiss
tend
lymphopenia
higher
infectionrel
biomark
ie
procalcitonin
erythrocyt
sediment
rate
serum
ferritin
creactiv
protein
sever
elev
inflammatori
cytokin
ie
tumor
necrosi
factor
tnf
interleukin
il
numer
differ
blood
cell
count
infect
relat
biomark
sever
group
nonsever
group
sever
case
higher
leukocyt
vs
p
neutrophil
vs
p
count
lower
lymphocyt
count
vs
p
higher
neutrophiltolymphocyt
ratio
nlr
vs
p
well
lower
percentag
monocyt
vs
p
eosinophil
vs
p
basophil
vs
p
compar
nonsever
group
sever
case
demonstr
elev
level
infectionrel
biomark
includ
procalcitonin
vs
ngml
p
serum
ferritin
vs
ngml
p
creactiv
protein
vs
mgl
p
bunch
inflammatori
cytokin
also
elev
sever
case
nonsever
one
includ
interleukin
il
vs
uml
p
vs
pgml
p
vs
pgml
p
vs
pgml
p
vs
pgml
p
immunoglobulin
iga
igg
igm
complement
protein
patient
within
normal
rang
signific
differ
level
iga
igg
complement
protein
mild
sever
group
igm
slightli
decreas
sever
one
lymphocyt
subset
analyz
patient
admiss
tabl
ul
evid
sever
case
vs
ul
p
compar
nonsever
group
mean
valu
three
main
subset
lymphocyt
gener
decreas
patient
cell
nk
cell
normal
level
b
cell
within
lower
level
normal
rang
cell
shown
affect
cell
count
nearli
half
lower
refer
limit
tend
hamper
sever
case
vs
ul
p
compar
nonsever
group
function
cell
nk
cell
indic
pmaionomycin
stimul
posit
cell
three
subset
within
normal
rang
signific
differ
found
sever
case
nonsever
one
report
dysregul
immun
system
cohort
patient
laboratori
confirm
wuhan
china
total
increas
nlr
lymphopeniain
particular
decreas
cellswer
common
among
patient
evid
sever
case
signific
chang
number
cell
b
cell
base
data
suggest
might
damag
lymphocyt
especi
lymphocyt
immun
system
impair
period
diseas
cohort
observ
patient
least
one
underli
disord
ie
hypertens
diabet
chronic
obstruct
pulmonari
diseas
higher
percentag
hypertens
cardiovascular
diseas
sever
case
mild
individu
consist
report
suggest
like
infect
elder
men
chronic
comorbid
due
weaker
immun
function
term
laboratori
test
note
infect
patient
present
lymphopenia
elev
level
infectionrel
biomark
interestingli
higher
number
neutrophil
lower
number
lymphocyt
ie
increas
neutrophiltolymphocyt
ratio
nlr
found
sever
group
compar
mild
group
nlr
wellknown
marker
system
inflamm
infect
studi
predictor
bacteri
infect
includ
pneumonia
increas
nlr
studi
consist
find
wang
et
al
sever
patient
rise
neutrophil
count
fall
lymphocyt
count
sever
phase
indic
seriou
disturb
intern
environ
potenti
critic
condit
sever
infect
case
higher
serum
level
proinflammatori
cytokin
chemokin
found
patient
sever
compar
individu
mild
diseas
similar
result
sar
mer
cytokin
chemokin
thought
play
import
role
immun
immunopatholog
viru
infect
although
direct
evid
involv
proinflammatori
cytokin
chemokin
lung
patholog
chang
laboratori
paramet
includ
elev
serum
cytokin
chemokin
level
increas
nlr
infect
patient
correl
sever
diseas
advers
outcom
suggest
possibl
role
hyperinflammatori
respons
pathogenesi
virusinduc
direct
cytopath
effect
viral
evas
host
immun
respons
believ
play
major
role
diseas
sever
rapid
wellcoordin
innat
immun
respons
first
line
defens
viral
infect
howev
immun
respons
dysregul
result
excess
inflamm
even
caus
death
studi
demonstr
pronounc
lymphopenia
low
count
cell
cell
case
differenti
tcell
effector
memori
subset
one
fundament
facet
tcellmedi
immun
balanc
memori
cell
crucial
maintain
effici
immun
respons
result
lymphocyt
subset
higher
tcell
subpopul
smaller
percentag
memori
cell
higher
memori
ratio
sever
case
indic
immun
system
sever
infect
subgroup
impair
sever
addit
decreas
regulatori
cell
especi
induc
regulatori
cell
key
role
restrain
allerg
inflamm
mucos
surfac
demonstr
infect
patient
especi
sever
group
furthermor
similar
tendenc
also
present
regulatori
cell
underli
control
system
tissu
specif
autoimmun
shown
cell
especi
cell
play
import
role
weaken
dampen
overact
innat
immun
respons
viral
infect
wherea
regulatori
cell
subset
helper
cell
play
crucial
role
neg
regul
activ
prolifer
effector
function
wide
rang
immun
cell
mainten
selftoler
immun
homeostasi
given
higher
express
proinflammatori
cytokin
chemokin
patient
especi
sever
case
consumpt
cell
decreas
regulatori
cell
present
studi
might
result
aggrav
inflammatori
respons
product
cytokin
storm
make
damag
tissu
wors
although
sure
correl
evid
sever
patient
lower
number
lymphocyt
suggest
role
dysregul
immun
respons
pathogenesi
sever
limit
studi
might
make
potenti
bia
first
retrospect
singl
center
small
sampl
studi
patient
admit
hospit
standard
data
larger
cohort
would
better
assess
tempor
chang
immun
respons
infect
second
patient
bacteri
coinfect
superinfect
might
affect
result
immun
respons
present
increas
nlr
procalcitonin
evid
sever
case
indic
potenti
bacteri
coinfect
due
dysregul
immun
system
despit
studi
demonstr
sever
novel
inform
dysregul
immun
respons
patient
might
mainli
act
lymphocyt
especi
lymphocyt
induc
cytokin
storm
bodi
gener
seri
immun
respons
damag
correspond
organ
thu
surveil
nlr
lymphocyt
subset
help
earli
screen
critic
ill
diagnosi
treatment
none
author
declar
compet
interest
leucocyt
per
l
tumor
necrosi
pgml
pgml
